new glp 1 agonist GLP-1 agonists approved for clinical use. GLP-1 agonists are available What are GLP-1s? | Mendinground
Description
FDA approved a new indication for semaglutide (Wegovy) to reduce the risk of cardiovascular death, myocardial infarction, and stroke in adults with CVD and either obesity or overweight (Lincoff et al., 2023)
High-dose oral semaglutide (Wegovy Tablet) Novo Nordisk have developed a higher-dose version of the semaglutide pill specifically for obesity
2013;166(240249):e241
Aminian A, Zajichek A, Arterburn DE, et al
Skip over navigation You appear to have JavaScript disabled in your browser
